Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide

Shedding light on an old mystery: Thalidomide suppresses survival pathways to induce limb defects

(2011) Jürgen Knobloch et al.   CELL CYCLE

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

(2009) P. Richardson et al.   BLOOD

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

(2009) M. Fulciniti et al.   BLOOD

Activation of Wnt/β-catenin signalling pathway induces chemoresistance to interferon-α/5-fluorouracil combination therapy for hepatocellular carcinoma

(2009) T Noda et al.   BRITISH JOURNAL OF CANCER

Glycogen synthase kinase 3: more than a namesake

(2009) Geetha Vani Rayasam et al.   BRITISH JOURNAL OF PHARMACOLOGY

Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism

(2009) L. Escoubet-Lozach et al.   CANCER RESEARCH

Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases

(2009) Bryan T. MacDonald et al.   DEVELOPMENTAL CELL

Transcriptional activation of the β‐cateningene at the invasion front of colorectal liver metastases

(2009) Obul R Bandapalli et al.   JOURNAL OF PATHOLOGY

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

(2009) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Proteasome inhibitors in the treatment of multiple myeloma

(2009) J J Shah et al.   LEUKEMIA

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

(2009) H Quach et al.   LEUKEMIA

The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/β-catenin pathway

(2009) M Flahaut et al.   ONCOGENE

Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction

(2008) Gondi Kumar et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Lenalidomide for the Treatment of B-Cell Malignancies

(2008) Asher A. Chanan-Khan et al.   JOURNAL OF CLINICAL ONCOLOGY

Bone marrow microenvironment and the identification of new targets for myeloma therapy

(2008) K Podar et al.   LEUKEMIA

Thalidomide and lenalidomide: Mechanism-based potential drug combinations

(2008) Sonia Vallet et al.   LEUKEMIA & LYMPHOMA

Thalidomide Resistance Is Based on the Capacity of the Glutathione-Dependent Antioxidant Defense

(2008) Jürgen Knobloch et al.   MOLECULAR PHARMACEUTICS